WO2017090157A1 - 血管新生抑制剤 - Google Patents
血管新生抑制剤 Download PDFInfo
- Publication number
- WO2017090157A1 WO2017090157A1 PCT/JP2015/083238 JP2015083238W WO2017090157A1 WO 2017090157 A1 WO2017090157 A1 WO 2017090157A1 JP 2015083238 W JP2015083238 W JP 2015083238W WO 2017090157 A1 WO2017090157 A1 WO 2017090157A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- angiogenesis
- angiogenesis inhibitor
- culturing
- vegf
- added
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to an angiogenesis inhibitor that suppresses angiogenesis.
- Angiogenesis is a physiological phenomenon in which new blood vessels branch from blood vessels, and plays an important role in organ formation, development of the corpus luteum, wound healing, etc. in the early stages of animal development. It is known that this excessive occurrence of angiogenesis is involved in many diseases such as malignant tumors, psoriasis, rheumatism, atherosclerosis, retinopathy (see Non-patent Documents 1 and 2).
- angiogenesis includes proliferation, differentiation, migration, luminal formation of vascular endothelial cells and the like.
- Angiogenesis is mainly controlled by several different growth factors and their receptors. Among these, vascular endothelial growth factor (VEGF) is considered to be the most important regulator in angiogenesis.
- VEGF vascular endothelial growth factor
- VEGF is a dimeric glycoprotein unique to endothelial cells. VEGF overexpression occurs in various tumors and causes tumor angiogenesis. VEGF is also overexpressed in other pathological conditions such as rheumatoid arthritis and retinal neovascularization.
- VEGFR2 VEGF receptor 1
- VEGFR2 VEGF receptor 2
- VEGF When VEGF binds to VEGFR2, receptor dimerization and autophosphorylation occur, resulting in phosphorylation and activation of several downstream signaling proteins including Akt, ERK1 / 2, p38 MAPK. These signaling proteins play an important role in cancer cell survival, proliferation, migration, and reorganization.
- angiogenesis inhibitors have been developed and used for the purpose of treatment and prevention.
- side effects such as hemoptysis, nosebleed, thrombosis, hypertension, proteinuria, and perforation are known for the angiogenesis inhibitors currently being developed.
- chronic diseases such as malignant tumors, rheumatism, and arteriosclerosis
- long-term administration is required and a safe anti-angiogenic agent is required, but use is limited due to side effects as described above. .
- the present invention has been made to solve the above-described problems, and an object thereof is to provide a drug effective for suppressing angiogenesis that causes disease.
- An angiogenesis inhibitor according to the present invention comprises a first step of degrading starch extracted from rice bran with glucoamylase to obtain a water-soluble polysaccharide extract, and L. lentinula edodes as basidiomycetes. Ammonium sulfate is added to the cultured culture filtrate, the second step of obtaining the enzyme complex from this precipitate, and the enzyme complex obtained in the second step is added to the water-soluble polysaccharide extract obtained in the first step. By reacting at pH 4.0 to 5.0 for 30 to 60 minutes and further reacting at pH 5.5 to 6.5 for 30 to 60 minutes, the water-soluble polysaccharide extract obtained in the first step is biologically decorated. The product produced by the third step of applying is used as an active ingredient and is used to suppress angiogenesis.
- the product is a polysaccharide complex.
- FIG. 1E is a photograph showing the results of culturing by adding 3 mg / mL of an angiogenesis inhibitor in addition to VEGF in a state where HUVECs and HDF coexist.
- FIG. 2A is a characteristic diagram showing the results of quantifying the area of the lumen 10 days after culturing in the presence of HUVECs and HDF in each condition by image data processing in observation with an optical microscope.
- FIG. 2B is a characteristic diagram showing the results of quantifying the length of the lumen 10 days after culturing in the presence of HUVECs and HDF in each condition by image data processing in observation with an optical microscope.
- FIG. 1E is a photograph showing the results of culturing by adding 3 mg / mL of an angiogenesis inhibitor in addition to VEGF in a state where HUVECs and HDF coexist.
- FIG. 2A is a characteristic diagram showing the results of quantifying the area of the lumen 10 days after culturing in the presence of HUVECs
- FIG. 2C is a characteristic diagram showing the result of quantification of the number of branch points in the lumen 10 days after culturing in the presence of HUVECs and HDF in each condition by image data processing in observation with an optical microscope.
- FIG. 2D is a characteristic diagram showing the results of quantification of the number of lumen branches 10 days after culturing in the presence of HUVECs and HDF in each condition by image data processing in observation with an optical microscope.
- FIG. 3 is a characteristic diagram showing the results of measuring the formazan product with a microplate reader in the culture results of each condition of Example 2.
- FIG. 4A is a photograph showing the result of culturing without adding anything in Example 3.
- FIG. 4B is a photograph showing the results of culture with VEGF added in Example 3.
- FIG. 4C is a photograph showing the results of culturing with the addition of 0.3 mg / mL of an angiogenesis inhibitor in addition to VEGF in Example 3.
- FIG. 4D is a photograph showing the results of culturing with the addition of 1 mg / mL of an angiogenesis inhibitor in addition to VEGF in Example 3.
- FIG. 4E is a photograph showing the results of culturing with the addition of 3 mg / mL of an angiogenesis inhibitor in addition to VEGF in Example 3.
- FIG. 5 is a characteristic diagram showing measurement by observation with an optical microscope of a cell migration state under each condition of Example 3.
- FIG. 6 is a photograph showing the results of Western blot analysis in a cell extract under each condition of HUVECs in Example 4.
- FIG. 5 is a characteristic diagram showing measurement by observation with an optical microscope of a cell migration state under each condition of Example 3.
- FIG. 6 is a photograph showing the results of Western blot analysis in a cell extract under each condition of HUV
- FIG. 7A is a characteristic diagram showing phosphorylation of VEGFR2 under each condition of the fourth embodiment.
- FIG. 7B is a characteristic diagram showing phosphorylation of Akt under each condition of the fourth embodiment.
- FIG. 7C is a characteristic diagram showing phosphorylation of ERK1 / 2 under each condition of the fourth embodiment.
- FIG. 7D is a characteristic diagram showing phosphorylation of p38 under each condition of the fourth embodiment.
- starch extracted from rice bran is decomposed with glucoamylase to obtain a water-soluble polysaccharide extract.
- a water-soluble polysaccharide extract For example, 5 liters of water is added to 1000 g of rice bran, heated to 100 ° C. and subjected to hot water extraction for 60 minutes, and then insoluble matters are filtered off.
- the starch in the filtered filtrate is hydrolyzed with glucoamylase to obtain a rice bran hemicellulose extract.
- hemicellulose can be used.
- hemicellulose of the grass family plant is excellent as a raw material.
- an enzyme complex is prepared by cultivating Lentinurda edodes of Bassidiomycetes.
- the lentinula ededes may be conventionally called lentinus edodes. This medium composition is shown in Table 1 below.
- the Enzyme-LE 3 g obtained was added to 4.5 liters of rice bran hemicellulose (water-soluble polysaccharide) extract, and the pH was first adjusted to 4.5. The mixture is reacted at 40 ° C. for 30 minutes, and further adjusted to pH 6.0 and reacted for 30 minutes to produce rice bran hemicellulose (RBX-LE: product) modified by Lentinula edodes extracellular enzyme.
- the initial reaction may be performed at pH 4.0 to 5.0 for 30 to 60 minutes. Further, the next reaction may be performed at a pH of 5.5 to 6.5 for 30 to 60 minutes.
- the produced product is an active ingredient of the angiogenesis inhibitor in the present embodiment.
- the main component of the substance serving as an active ingredient is xylan mainly composed of ⁇ -1,4 xylopyranose chains.
- the product produced as described above is sterilized, sterilized and concentrated as it is, it can be used as a liquid agent for an angiogenesis inhibitor. Furthermore, it can be pulverized by freeze-drying or spray-drying and used as an angiogenesis inhibitor for tablets and granules.
- Example 1 First, Example 1 will be described.
- human umbilical vein endothelial cells (HUVECs) and human skin fibroblasts (HDF) are targeted as angiogenesis suppression models.
- Example 2 Next, Example 2 will be described.
- HUVECs are targeted as an angiogenesis suppression model.
- FIGS. 4A, 4B, 4C, 4D, and 4E The optical micrographs of each sample are shown in FIGS. 4A, 4B, 4C, 4D, and 4E.
- FIG. 4A is a photograph showing the result of culturing without adding anything.
- FIG. 4B is a photograph showing the results of culturing with VEGF added.
- FIG. 4C is a photograph showing the results of culturing with 0.3 mg / mL of an angiogenesis inhibitor in addition to VEGF.
- FIG. 4D is a photograph showing the results of culturing with 1 mg / mL of an angiogenesis inhibitor added to VEGF.
- FIG. 4E is a photograph showing the results of culturing with 3 mg / mL of an angiogenesis inhibitor in addition to VEGF.
- Example 4 Next, Example 4 will be described.
- HUVECs are targeted as an angiogenesis suppression model.
- HUVECs were analyzed by Western blot. HUVECs were pre-cultured for 30 minutes with and without angiogenesis inhibitor (3 mg / mL), added with VEGF (10 ng / mL), and cultured for 15 minutes. Proteins were extracted by dissolving HUVECs, centrifuging, and collecting the supernatant. The extracted protein was analyzed by Western blot. Images were captured with an image capturing device “Ez-Capture MG AE-9300 (manufactured by Atto Corporation)” and analyzed with analysis software “CS Analyzer 3.0 (manufactured by Atto Corporation)”. FIG. 6 shows the result of capturing an image. The analysis results are shown in FIGS. 7A, 7B, 7C, and 7D.
- HUVECs increased phosphorylation of vascular endothelial growth factor receptor VEGFR2, serine / threonine kinase Akt, mitogen-activated protein kinase ERK1 / 2, and p38 by adding VEGF.
- VEGFR2 vascular endothelial growth factor receptor 2
- serine / threonine kinase Akt serine / threonine kinase Akt
- mitogen-activated protein kinase ERK1 / 2 mitogen-activated protein kinase ERK1 / 2
- p38 mitogen-activated protein kinase ERK1 / 2
- angiogenesis inhibitor of the present invention is effective in suppressing angiogenesis that causes disease.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
始めに、実施例1について説明する。実施例1では、血管新生抑制モデルとして、ヒト臍帯静脈内皮細胞(HUVECs)およびヒト皮膚線維芽細胞(HDF)を対象とする。
HUVECsとHDFとを共存させ、10ng/mLのVEGFを加えた場合と加えない場合、実施の形態における血管新生抑制剤を加えた場合と加えない場合についてそれぞれ培養した。血管新生抑制剤については、添加量を、0.3mg/mL、1mg/mL、3mg/mLの3点とした。
定量の結果、図2A,図2B,図2C,図2Dに示すように、血管の面積、長さ、分岐点数、枝数のいずれにおいても、実施の形態における血管新生抑制剤を添加した場合、濃度依存的に管腔形成を抑制していることが示された。実施の形態における血管新生抑制剤を添加した場合、面積は3mg/mL、長さ、分岐点数、枝数は、1および3mg/mLで、VEGFのみ添加した場合に比べ有意な差が認められた。
次に、実施例2について説明する。実施例2では、血管新生抑制モデルとして、HUVECsを対象とする。
HUVECsを24時間培養した後、10ng/mLのVEGFを加えた場合と加えない場合、実施の形態における血管新生抑制剤を加えた場合と加えない場合について、さらに72時間それぞれ培養した。血管新生抑制剤については、添加量を、0.3mg/mL、1mg/mL、3mg/mLの3点とした。また、培養した各サンプルに対し、10μLのMTTを添加し、4時間経過後のホルマザン生成物をマイクロプレートリーダーで測定した。
測定の結果、図3に示すように、実施の形態における血管新生抑制剤は、濃度依存的にHUVECsの増殖を抑制していることが示された。添加した血管新生抑制剤の量が多いほど、HUVECsの増殖が抑制されている。血管新生抑制剤の添加量が、1mg/mLおよび3mg/mLで、VEGFは添加して血管新生抑制剤は添加していない場合(control)に比べ有意な差が認められた。
次に、実施例3について説明する。実施例3では、血管新生抑制モデルとして、HUVECsを対象とし、細胞の遊走状態を測定した。
細胞の遊走を測定するため、コラーゲンでコーティングした容器にHUVECsが1層で成育するように24時間培養した。培養により、容器の底にシート状にHUVECsが成長した。シート状に成育したHUVECsの層を無菌的にひっかき、細胞がない部分を作製した。ひっかくことにより浮遊した細胞を取り除き、10ng/mLのVEGFを加えた場合と加えない場合、実施の形態における血管新生抑制剤を加えた場合と加えない場合について、21時間それぞれ培養した。血管新生抑制剤については、添加量を、0.3mg/mL、1mg/mL、3mg/mLの3点とした。
遊走状態の計測の結果、図5に示すように、血管新生抑制剤は、濃度依存的にHUVECsの遊走を抑制していることが示された。添加した血管新生抑制剤の量が多いほど、HUVECsの遊走が抑制されている。血管新生抑制剤の添加量が、1mg/mLおよび3mg/mLで、VEGFは添加して血管新生抑制剤は添加していない場合(control)に比べ有意な差が認められた。
次に、実施例4について説明する。実施例4では、血管新生抑制モデルとして、HUVECsを対象とする。
血管新生抑制剤の効果が、VEGFR2とその下流の情報伝達タンパク質の抑制に関与するかどうか調べるため、HUVECsをウエスタンブロットにより分析した。HUVECsを血管新生抑制剤(3mg/mL)がある場合とない場合で30分間前培養し、そこにVEGF(10ng/mL)添加し15分間培養した。HUVECsを溶解し、遠心分離し、上清を分取することで、タンパク質を抽出した。抽出したタンパク質をウエスタンブッロトにより解析した。画像取り込み装置「Ez-Capture MG AE-9300(アトー株式会社製)」で画像を取り込み、解析ソフトウエア「CS Analyzer 3.0(アトー株式会社製)」で解析した。画像の取り込み結果を図6に示す。また、解析結果を図7A、図7B、図7C、図7Dに示す。
解析の結果、HUVECsは、VEGFの添加により、血管内皮細胞増殖因子受容体であるVEGFR2、セリン・スレオニンキナーゼであるAkt、分裂促進因子活性化タンパク質キナーゼであるERK1/2、p38のリン酸化が増加することが判明した。また、血管新生抑制剤の前処理が、上述した血管新生に関わる各情報伝達タンパク質のリン酸化を抑制することが示された。なお、図6の「β-actin」に示すように、アプライした各HUVECs抽出液中サンプルのタンパク質の総量は全てにおいて等しい。
Claims (2)
- 米糠より抽出したでんぷんをグルコアミラーゼで分解して水溶性多糖体抽出液を得る第1過程と、
バシディオミセテス類のレンチニュラエドデス(Lentinula edodes)を培養した培養濾液に硫酸アンモニウムを加え、この沈澱物から酵素の複合体を得る第2過程と、
前記第1過程で得た水溶性多糖体抽出液に前記第2過程で得た酵素の複合体を加えてpH4.0~5.0で30~60分反応させ、さらにpH5.5~6.5で30~60分反応させることによって、前記第1過程で得た水溶性多糖体抽出液に生物学的装飾を施す第3過程と
により生成した生成物質を有効成分として含み、
血管新生の抑制に用いられることを特徴とする血管新生抑制剤。 - 請求項1記載の血管新生抑制剤において、前記生成物質は、多糖複合体であることを特徴とする血管新生抑制剤。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017552614A JP6521276B2 (ja) | 2015-11-26 | 2015-11-26 | 血管新生抑制剤 |
CN201580084717.1A CN108430488B (zh) | 2015-11-26 | 2015-11-26 | 血管生成抑制剂 |
US15/779,021 US20180325976A1 (en) | 2015-11-26 | 2015-11-26 | Angiogenesis inhibitor |
EP15909274.1A EP3381460A4 (en) | 2015-11-26 | 2015-11-26 | INHIBITOR OF ANGIOGENESIS |
PCT/JP2015/083238 WO2017090157A1 (ja) | 2015-11-26 | 2015-11-26 | 血管新生抑制剤 |
TW105138362A TWI606831B (zh) | 2015-11-26 | 2016-11-23 | 血管新生抑制劑 |
US16/400,849 US10709753B2 (en) | 2015-11-26 | 2019-05-01 | Method of inhibiting angiogenesis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2015/083238 WO2017090157A1 (ja) | 2015-11-26 | 2015-11-26 | 血管新生抑制剤 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/779,021 A-371-Of-International US20180325976A1 (en) | 2015-11-26 | 2015-11-26 | Angiogenesis inhibitor |
US16/400,849 Division US10709753B2 (en) | 2015-11-26 | 2019-05-01 | Method of inhibiting angiogenesis |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017090157A1 true WO2017090157A1 (ja) | 2017-06-01 |
Family
ID=58764170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/083238 WO2017090157A1 (ja) | 2015-11-26 | 2015-11-26 | 血管新生抑制剤 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20180325976A1 (ja) |
EP (1) | EP3381460A4 (ja) |
JP (1) | JP6521276B2 (ja) |
CN (1) | CN108430488B (ja) |
TW (1) | TWI606831B (ja) |
WO (1) | WO2017090157A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020166063A1 (ja) * | 2019-02-15 | 2020-08-20 | 大和薬品株式会社 | フレイル改善方法およびフレイル改善食品 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0923895A (ja) * | 1995-07-12 | 1997-01-28 | Daiwa Yakuhin Kk | 免疫力増強物質及びその製造方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5997875A (en) * | 1998-03-27 | 1999-12-07 | Zhou; James H. | Herbal composition and treatment methods |
SK242001A3 (en) * | 1998-07-06 | 2001-10-08 | Merck Patent Gmbh | Rdg mimetic compound, method for their producing and method for differentiation inhibiting of cell adhesion |
KR20030030636A (ko) * | 2001-10-12 | 2003-04-18 | 주식회사 싸이제닉 | 버섯 자실체의 발효를 이용하여 고활성 항암 단백다당체를제조하는 방법 |
CN101316590B (zh) * | 2005-11-07 | 2011-08-03 | 卫材R&D管理有限公司 | 血管生成抑制剂和c-kit激酶抑制剂的组合使用 |
JP5358219B2 (ja) * | 2009-02-26 | 2013-12-04 | 大和薬品株式会社 | 腸疾患治療剤 |
-
2015
- 2015-11-26 WO PCT/JP2015/083238 patent/WO2017090157A1/ja active Application Filing
- 2015-11-26 EP EP15909274.1A patent/EP3381460A4/en not_active Withdrawn
- 2015-11-26 US US15/779,021 patent/US20180325976A1/en not_active Abandoned
- 2015-11-26 CN CN201580084717.1A patent/CN108430488B/zh active Active
- 2015-11-26 JP JP2017552614A patent/JP6521276B2/ja active Active
-
2016
- 2016-11-23 TW TW105138362A patent/TWI606831B/zh active
-
2019
- 2019-05-01 US US16/400,849 patent/US10709753B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0923895A (ja) * | 1995-07-12 | 1997-01-28 | Daiwa Yakuhin Kk | 免疫力増強物質及びその製造方法 |
Non-Patent Citations (5)
Title |
---|
GHONEUM,MAMDOOH ET AL.: "Modified arabinoxylan from rice bran, MGN-3/Biobran, sensitizes metastatic breast cancer cells to paclitaxel in Vitro", ANTICANCER RESEARCH, vol. 34, no. 1, 2014, pages 81 - 87, XP055487983 * |
HIROAKI YAZAMA ET AL.: "Komenuka Yurai Glucosylceramide no Ko-Shuyo Koka to Kekkan Shinsei eno Eikyo", JAPANESE JOURNAL OF HEAD AND NECK CANCER, vol. 38, no. 2, 2012, pages 226 , 357, XP009506707 * |
J. FOLKMAN: "Angiogenesis in cancer, vascular, rheumatoid and other disease", NATURE MEDICINE, vol. 1, 1995, pages 27 - 31, XP000605147, DOI: doi:10.1038/nm0195-27 |
N. FERRARA: "Role of vascular endothelial growth factor in the regulation of angiogenesis", KIDNEY INTERNATIONAL, vol. 56, 1999, pages 794 - 814 |
See also references of EP3381460A4 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020166063A1 (ja) * | 2019-02-15 | 2020-08-20 | 大和薬品株式会社 | フレイル改善方法およびフレイル改善食品 |
Also Published As
Publication number | Publication date |
---|---|
CN108430488B (zh) | 2021-03-12 |
JPWO2017090157A1 (ja) | 2018-07-26 |
TWI606831B (zh) | 2017-12-01 |
US20190255137A1 (en) | 2019-08-22 |
JP6521276B2 (ja) | 2019-05-29 |
EP3381460A4 (en) | 2019-07-17 |
CN108430488A (zh) | 2018-08-21 |
US20180325976A1 (en) | 2018-11-15 |
US10709753B2 (en) | 2020-07-14 |
EP3381460A1 (en) | 2018-10-03 |
TW201720449A (zh) | 2017-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kała et al. | Fruiting bodies of selected edible mushrooms as a potential source of lovastatin | |
Wang et al. | Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer | |
CN104955473B (zh) | 结合egfr和c-met iii型纤连蛋白域的分子 | |
Wong et al. | Activity of aqueous extracts of lion's mane mushroom Hericium erinaceus (Bull.: Fr.) Pers.(Aphyllophoromycetideae) on the neural cell line NG108-15 | |
SG170730A1 (en) | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 | |
CN108883088A (zh) | 利用色酮衍生物的上皮间质转化抑制活性的作为纤维化预防及治疗用药剂学组合物的新用途 | |
Hamrun et al. | Toxicity test of bioactive red alga extract Eucheuma spinosum on shrimp Artemia salina leach | |
WO2017090157A1 (ja) | 血管新生抑制剤 | |
CN110903348A (zh) | 一种促进伤口愈合的小肽及其应用 | |
CN104039337B (zh) | 对皮肤应答于外部刺激的镇静剂和用于镇静该应答的方法 | |
Zabirnyk et al. | SNF472, a novel anti-crystallization agent, inhibits induced calcification in an in vitro model of human aortic valve calcification | |
Rocha et al. | Inhibitory effects of dabigatran etexilate, a direct thrombin inhibitor, on osteoclasts and osteoblasts | |
Prabhu et al. | In vitro and in silico analyses of Vicia faba L. on Peroxisome proliferator–activated receptor gamma | |
CN108410878A (zh) | 一种lrpprc特异性核酸适配体及其应用 | |
Basmaji et al. | Skin Cancer Treatment by Nanoskin Cellulose: Future Cancer Wound Healing | |
CN102048727A (zh) | 芒柄花黄素在制备抑制血管生成药物中的应用 | |
CN105120836B (zh) | 具有胶原蛋白合成能力的新型的肽及其用途 | |
WO2020000828A1 (zh) | 一种具有显著降血脂活性的龙须菜多糖及其制备方法与应用 | |
Li et al. | Inhibitory effect of icaritin on proliferation, migration, and invasion of human nasopharyngeal carcinoma cell CNE2 by regulating STAT3 activation | |
Gentimir et al. | Biochemical effects of some tyrosine kinase inhibitors on pro-B cells-induced apoptosis | |
JP2018083807A (ja) | 免疫チェックポイント阻害機能を有する抗癌剤耐性抑制剤及びその製造方法 | |
Herculano et al. | Recent advances and perspectives on natural latex serum and its fractions for biomedical applications | |
CN109833321A (zh) | 一种逆转肝癌细胞对sorafenib耐药性的药物组合物 | |
Javan-Jaafari-Bojnourdi et al. | The effect of alcoholic extract of Persian gulf chiton (lamyi) shell on angiogenesis in chick chorioallantoic membrane | |
Zhang et al. | The expression of TP53 pathway-related proteins in ovarian carcinoma transplanted subcutaneously in nude mice. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15909274 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017552614 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15779021 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015909274 Country of ref document: EP |